- Home
- VGI vs ANIX Comparison
VGI vs ANIX Comparison
Compare VGI & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VGI | ANIX |
|---|---|---|
| Founded | 2012 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.8M | 104.0M |
| IPO Year | N/A | 1987 |
Fundamental Metrics
Financial Performance| Metric | VGI | ANIX |
|---|---|---|
| Price | $7.98 | $2.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 46.0K | ★ 232.5K |
| Earning Date | 01-01-0001 | 03-10-2026 |
| Dividend Yield | ★ 12.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.68 | $2.33 |
| 52 Week High | $7.99 | $5.46 |
Technical Indicators
Market Signals| Indicator | VGI | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 65.96 | 41.99 |
| Support Level | $7.83 | $2.69 |
| Resistance Level | $7.98 | $3.00 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 93.17 | 38.64 |
Price Performance
Historical ComparisonAbout VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.